281 related articles for article (PubMed ID: 16278377)
1. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
Yaccoby S
Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
[TBL] [Abstract][Full Text] [Related]
2. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
[TBL] [Abstract][Full Text] [Related]
5. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
6. Characterization of in vitro growth of multiple myeloma cells.
Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
[TBL] [Abstract][Full Text] [Related]
7. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
11. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
12. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
Ridley RC; Xiao H; Hata H; Woodliff J; Epstein J; Sanderson RD
Blood; 1993 Feb; 81(3):767-74. PubMed ID: 8427968
[TBL] [Abstract][Full Text] [Related]
13. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
17. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
18. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state.
Pope B; Brown RD; Gibson J; Petersen A; Wiley J; Joshua DE
Leuk Lymphoma; 1997 Sep; 27(1-2):83-91. PubMed ID: 9373199
[TBL] [Abstract][Full Text] [Related]
19. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
20. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
